Robot-assisted nephroureterectomy for upper tract urothelial carcinoma-feasibility and complications: a single center experience.

IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY
Scandinavian Journal of Urology Pub Date : 2022-08-01 Epub Date: 2022-06-23 DOI:10.1080/21681805.2022.2091018
F Liedberg, J Abrahamsson, J Bobjer, S Gudjonsson, A Löfgren, M Nyberg, A Sörenby
{"title":"Robot-assisted nephroureterectomy for upper tract urothelial carcinoma-feasibility and complications: a single center experience.","authors":"F Liedberg,&nbsp;J Abrahamsson,&nbsp;J Bobjer,&nbsp;S Gudjonsson,&nbsp;A Löfgren,&nbsp;M Nyberg,&nbsp;A Sörenby","doi":"10.1080/21681805.2022.2091018","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Robot-assisted nephroureterectomy (RANU) is the primary treatment for upper tract urothelial carcinoma (UTUC) at our hospital for patients with clinical stage less than T2, and for patients with invasive tumours, but unfit for major surgery.</p><p><strong>Objective: </strong>To assess peri-operative conditions and outcomes of RANU at our unit, and to evaluate the safety of the procedure.</p><p><strong>Methods: </strong>The medical records of all 166 patients undergoing RANU for suspected UTUC and followed for more than three months in a large university hospital in Sweden were reviewed retrospectively. After the exclusion of twenty patients because of previous cystectomy, simultaneous surgical procedure, or other tumour types than UTUC in the pathological report, 146 patients remained for the analyses. The primary endpoint was complication rate according to Clavien-Dindo at 90 days. Secondary endpoints were perioperative bleeding, violation of oncological surgical principles, hospital stay, and re-admission within 90 days.</p><p><strong>Results: </strong>The median age was 75 [(Inter Quartile Range) IQR 70-80] years and 57% of the patients had an ASA score above 2. According to Clavien-Dindo, one patient had a grade 3 complication, and no patient had a grade 4-5 complication. The median blood loss was 50 (IQR 20-100) ml and the median hospital stay was 6 (IQR 5-7) days. Twelve patients were re-admitted to the hospital within 90 days (eight with urinary tract infection/haematuria, one with hematoma, and three with other diseases).</p><p><strong>Conclusion: </strong>Robot-assisted nephroureterectomy is a safe procedure for patients with upper tract urothelial carcinoma, with a low risk of major surgical complications.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21681805.2022.2091018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Robot-assisted nephroureterectomy (RANU) is the primary treatment for upper tract urothelial carcinoma (UTUC) at our hospital for patients with clinical stage less than T2, and for patients with invasive tumours, but unfit for major surgery.

Objective: To assess peri-operative conditions and outcomes of RANU at our unit, and to evaluate the safety of the procedure.

Methods: The medical records of all 166 patients undergoing RANU for suspected UTUC and followed for more than three months in a large university hospital in Sweden were reviewed retrospectively. After the exclusion of twenty patients because of previous cystectomy, simultaneous surgical procedure, or other tumour types than UTUC in the pathological report, 146 patients remained for the analyses. The primary endpoint was complication rate according to Clavien-Dindo at 90 days. Secondary endpoints were perioperative bleeding, violation of oncological surgical principles, hospital stay, and re-admission within 90 days.

Results: The median age was 75 [(Inter Quartile Range) IQR 70-80] years and 57% of the patients had an ASA score above 2. According to Clavien-Dindo, one patient had a grade 3 complication, and no patient had a grade 4-5 complication. The median blood loss was 50 (IQR 20-100) ml and the median hospital stay was 6 (IQR 5-7) days. Twelve patients were re-admitted to the hospital within 90 days (eight with urinary tract infection/haematuria, one with hematoma, and three with other diseases).

Conclusion: Robot-assisted nephroureterectomy is a safe procedure for patients with upper tract urothelial carcinoma, with a low risk of major surgical complications.

机器人辅助肾输尿管切除术治疗上尿路上皮癌的可行性和并发症:单中心经验。
背景:机器人辅助肾输尿管切除术(RANU)是我院治疗上尿路上皮癌(UTUC)的主要治疗方法,适用于临床分期小于T2的患者,以及侵袭性肿瘤患者,但不适合进行大手术。目的:评价我院RANU手术的围手术期情况及疗效,评价RANU手术的安全性。方法:回顾性分析瑞典某大型大学医院166例疑似UTUC行RANU治疗并随访3个月以上的病例。在排除了20例因既往膀胱切除术、同时手术或病理报告中其他肿瘤类型而非UTUC的患者后,仍有146例患者用于分析。主要终点是90天时Clavien-Dindo的并发症发生率。次要终点为围手术期出血、违反肿瘤手术原则、住院时间和90天内再次入院。结果:中位年龄为75[(四分位间距)IQR 70-80]岁,57%的患者ASA评分在2分以上。Clavien-Dindo表示,1名患者出现3级并发症,没有患者出现4-5级并发症。中位失血量为50 (IQR 20-100) ml,中位住院时间为6 (IQR 5-7)天。12例患者在90天内再次入院(8例患有尿路感染/血尿,1例患有血肿,3例患有其他疾病)。结论:机器人辅助肾输尿管切除术对于上尿路上皮癌患者是一种安全的手术,主要手术并发症的风险低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Scandinavian Journal of Urology
Scandinavian Journal of Urology UROLOGY & NEPHROLOGY-
CiteScore
2.90
自引率
6.70%
发文量
70
期刊介绍: Scandinavian Journal of Urology is a journal for the clinical urologist and publishes papers within all fields in clinical urology. Experimental papers related to clinical questions are also invited.Important reports with great news value are published promptly.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信